n the central nervous system, the serotonin transporter (SERT) modulates serotoninergic signaling by carrying out the uptake of serotonin (5-HT) from the synaptic space into presynaptic neurons 1 . 5-HT influences many aspects of behavior, including memory, learning, sleep, hunger, pain, sexual function, and mood 2 . A substantial number of nonsynonymous single-nucleotide polymorphisms are known to affect 5-HT transport and are enriched in families with psychiatric disorders, including obsessive-compulsive disorder and Asperger's syndrome 3 . Moreover, SERT is the primary target of therapeutic drugs used in the treatment of major depression, anxiety disorders, and attention-deficient hyperactivity disorder 1 . 5-HT is also found in the circulatory system, where it acts as a vasoconstrictor, and altered plasma concentrations of 5-HT have been implicated in several pathologies, including hypertension 4 . The plasma levels of 5-HT are regulated by SERT, which stores 5-HT in platelets, thus ensuring stable blood flow 5 . Transporters for dopamine (DAT) and norepinephrine are related to SERT in amino acid sequence and in biological function, and are also well-established targets for pharmacological agents that influence brain chemistry 6 . These monoamine transporters exploit the ion gradients of Na + and Cl -, thus rendering neurotransmitter uptake thermodynamically favorable 7 . Monoamine transporters have 12 transmembrane helices (TMs), and TMs 1-5 and TMs 6-10 form an inverted-topological repeat containing a central binding site for substrate and ions approximately halfway across the membrane [8] [9] [10] . An extracellular vestibule in the outward-facing conformation 8,10,11 forms a secondary, allosteric site, which, when occupied by ligands, can modulate transporter activity by altering the kinetics of ligand dissociation from the central site [12] [13] [14] . Addictive substances such as cocaine and amphetamine bind to monoamine transporters and can either inhibit neurotransmitter transport or promote neurotransmitter efflux, respectively 15, 16 . Selective serotonin reuptake inhibitors (SSRIs) are a class of small molecules that are highly selective for SERT over DAT and norepinephrine, and that inhibit 5-HT reuptake with nanomolar potency (Fig. 1a) ; as a consequence, these compounds bind with a range of affinities to SERT. Sertraline contains a tetrahydronaphthalene-ring system linked to a secondary amine together with a meta-and para-substituted dichlorophenyl group. Fluvoxamine, in contrast, consists of a 2-aminoethyloxime moiety attached to a methyoxybutyl group and a phenyl group containing a trifluoronated methyl at the para positon. Fluoxetine also contains a trifluoronated aromatic group but is instead coupled to a phenylpropylamine moiety. Paroxetine and citalopram also differ substantially in the structures of their aromatic, amine, and halogenated substituents.
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SSRIs have diverse chemical structures and, in many instances, do not share common structural motifs. The diversity of SSRI chemical structures results in compounds with substantial pharmacological differences 19 . For example. sertraline and fluvoxamine differ in chemical structure from other SSRIs such as paroxetine, citalopram, and fluoxetine (Fig. 1a) ; as a consequence, these compounds bind with a range of affinities to SERT. Sertraline contains a tetrahydronaphthalene-ring system linked to a secondary amine together with a meta-and para-substituted dichlorophenyl group. Fluvoxamine, in contrast, consists of a 2-aminoethyloxime moiety attached to a methyoxybutyl group and a phenyl group containing a trifluoronated methyl at the para positon. Fluoxetine also contains a trifluoronated aromatic group but is instead coupled to a phenylpropylamine moiety. Paroxetine and citalopram also differ substantially in the structures of their aromatic, amine, and halogenated substituents.
Recently, we have solved X-ray structures of a thermostable, transport-inactive construct of human SERT, denoted the ts3 construct, in complex with the SSRIs paroxetine and citalopram 9 . We used the thermostable variant of SERT to facilitate purification and crystallization 20, 21 . However, one of the thermostabilizing mutations involves a residue (T439S) that is directly positioned within the central binding site, close to the bound SSRIs. Moreover, recent computational modeling of a wild-type SERT-paroxetine complex, in which the structure of the Drosophila DAT was used as a template for the SERT structure, has yielded a pose for paroxetine in the SERT binding site that is different from that found in the SERT ts3 crystal structure 22 . In light of the computational study and because residue 439 is near the central binding site, we were motivated to determine crystal structures of SSRI-bound SERT in which residue 439 is the wild-type threonine amino acid.
Despite the importance of SSRIs in medicine and in the biophysical study of SERT, there is little structural explanation for how these diverse ligands bind to SERT 23 . Until recently, the structural understanding of how SSRIs bind to SERT has been largely guided by studies of the bacterial homolog LeuT 24, 25 , computational modeling [26] [27] [28] [29] [30] , and, more recently, the structures of SERT in complex with parox- . We reasoned that to accommodate various SSRIs within the central binding site, residues lining the central binding site might adopt different conformations. Thus we determined X-ray structures of Thr439 ts2 SERT in complex with paroxetine and the structure of the ts3 transporter bound to sertraline and fluvoxamine. These structures provide insight into how different SSRIs are bound within the central binding site of SERT.
results
Binding of antidepressants to ts2 and ts3 transporters. To probe the capacity of the ts3 and ts2 transporters to bind antidepressants, we first carried out binding studies using [ Fig. 1c-g ). With the exception of sertraline, SSRIs bound with slightly lower affinity to ts3 than to ts2. The K i values were 10 ± 1 and 7 ± 1 nM for (S)-citalopram ( Fig. 1c , P > 0.05); 2.0 ± 0.2 and 7 ± 1 nM for sertraline ( Fig. 1d , P > 0.05); 35 ± 3 and 10 ± 1 nM for (S)-fluoxetine ( Fig. 1e , P < 0.05); 41 ± 4 and 9 ± 1 nM for (R)-fluoxetine ( Fig. 1f , P < 0.05); and 69 ± 9 and 10 ± 2 nM for fluvoxamine ( Fig. 1g , P < 0.05) binding to ts3 and ts2, respectively. These dissociation constants and the relative differences in the dissociation constants among the SSRIs agree well with findings from previous reports 31 . The presence of the Y110A mutant in both the ts3 and the ts2 variants renders them inactive in 5-HT transport 20 .
Transporter-antidepressant interactions at the central site. The structure of paroxetine bound to ts2 was determined with diffraction data extending to a Bragg spacing of 3.6 Å. The electron density for several of the side chains for residues in the intracellular gate and within the C-terminal hinge and helix was also better resolved in the ts2 structure reported here than in the previously reported ts3 structure, thus allowing for more comprehensive modeling of these regions ( Supplementary Fig. 1 ), including part of the recognition sequence for SEC24C 32, 33 . Despite the moderate resolution of the diffraction data, the electron density features in the central site were of sufficient quality to allow us to position paroxetine. We found that the piperidine ring is best accommodated in subsite A, the benzodioxol is best accommodated in subsite B, and the fluorophenyl group is best accommodated in subsite C ( Fig. 2a and Table 1 ). Fitting of paroxetine in the opposite orientation, with the benzodioxol in subsite C and the fluorophenyl in subsite B, yields a poor fit to the electron density and produces clashes in subsites A and C (Supplementary Fig. 2 ). The sertraline and fluvoxamine structures were solved in complex with ts3 at 3.5-Å and 3.8-Å resolution, respectively. Omit maps and anomalous difference Fourier maps were used to position sertraline with the dichlorophenyl ring in subsite B and the amine and tetrahydronaphthalene groups in subsites A and C, respectively (Fig. 2b,c) . The density for fluvoxamine was not continuous, but we found density for the aminoethyloxime and trifluoro aromatic groups in subsites A and B (Fig. 2d) ; no density was observed for the methyoxybutyl moiety, probably because of its flexibility. A Polder 'omit' map 34 was used to further recover fluvoxamine density and to position it more accurately within subsites A and B. The placement of residues involved in drug binding at the central site was guided by electron density features and by chemical interactions with the drug (Supplementary Fig. 3) . No density was observed in the allosteric site with the sertraline and fluvoxamine complexes, in agreement with sertraline being a less potent allosteric inhibitor of the dissociation of citalopram from the central site than citalopram 13 . At present, there is no information on whether fluvoxamine binds the allosteric site and influences ligand dissociation from the central site.
The structure of the ts2 SERT variant in complex with paroxetine revealed only minor perturbations in the pose of the inhibitor and the conformations of residues involved in ligand binding in comparison to the ts3-paroxetine structure (Fig. 3a,b) . We believe that this similarity is because the hydroxyl group of threonine 439 faces subsite B, as does the serine at this position, and thus both residues are in a position to participate in interactions with ligands in the central site. We speculate that the ts2 variant has a higher affinity for paroxetine at least in part because the hydroxyl of Ser439 is closer (3.9 Å) than the hydroxyl of Thr439 (5.2 Å) to the ligand benzodioxol oxygen. A recent study using photo-cross-linking also favors a placement of paroxetine consistent with that in our structures 35 . However, further studies at higher resolution will be required to more definitively define the transporter-ligand interactions.
The amine groups of sertraline and fluvoxamine also occupy subsite A, interacting with Asp98 and Try95 (Fig. 3c,d ), residues crucial for drug binding [36] [37] [38] . In subsite B, Ser439 is within 4.5 and 3.9 Å of the halide atoms of sertraline and fluvoxamine while aromatic interactions are formed between Tyr176 and the drugs. The side chain of Ile172 adopts a similar conformation to that in the paroxetine state, fitting snugly between substituents in subsites B and C. In subsite C, Phe341 forms a face-to-face interaction with the naphthalene ring of sertraline while Phe335 forms a face-to-edge interaction with the naphthalene moiety. In the fluvoxamine complex, Phe341 (ref. 26 ) assumes a rotameric conformation similar to that in the sertraline complex, whereas the conformation of Phe335 is closer to that observed in the paroxetine structures.
Discussion
Comparisons of the structures of the sertraline and fluvoxamine complexes to the previously determined structures of SERT with paroxetine and (S)-citalopram reveal important differences in the positions of the residues in subsite C. In the sertraline complex, relative to the paroxetine and (S)-citalopram complexes, Phe341 has flipped 'upward' , filling a space that is unoccupied by ligand, and thus can interact with the naphthalene ring of sertraline; Phe335 undergoes a rotation of ~90° about its Cβ -Cγ bond (chi2) to accommodate the conformational change of Phe341 (Fig. 4a) . In the fluvoxamine complex, Phe341 is in a position similar to that in the sertraline complex, but Phe335 adopts a conformation more similar to that in the paroxetine and (S)-citalopram complexes (Fig. 4b,c) . We also note that Thr497 is shifted by ~1 Å (Cα -Cα distance) in the sertraline and fluvoxamine complexes in comparison to the paroxetine complexes, probably because paroxetine is the only drug with a fluorinated substituent in subsite C, a substituent that interacts with Thr497. Superposition of all four SSRI complexes revealed different placements of the various drug substituents within the central binding site (Fig. 4d-j) , thus resulting in differences in van der Waals (> 4 Å), aromatic (4.5-7 Å) 39 , and ionic (~4 Å) 40 interactions. We caution that, because of the modest resolution, the accuracy of these measurements contains some degree of error. We estimated the standard uncertainty in the ligand position by calculating the coordinate error measured by the diffraction precision index 41 . The uncertainty is 0.4 Å for the paroxetine ligand, 0.5 Å for sertraline, 0.6 Å for fluvoxamine, and 0.3 Å for (S)-citalopram. In subsite A, the distance from the amine of sertraline and (S)-citalopram to Asp98 is longer, whereas the distance to the amine of fluvoxamine and paroxetine is shorter. In contrast, the positioning of the amine to Tyr95 is farther for fluvoxamine and paroxetine, whereas the amine of (S)-citalopram and sertraline is more equally posed between Asp98 and Tyr95. In subsite B, the meta chlorine of sertraline and the fluorine of (S)-citalopram engages with Ser439 while the fluorines of fluvoxamine and the oxygen of paroxetine form even closer interactions with Ser439/Thr439, though the distance is not sufficiently close to form a hydrogen bond to the halides 42 . The shorter distance to Ser439/Thr439 in the fluvoxamine complex and in the ts2-paroxetine versus the ts3-paroxetine complexes may also explain, at least in part, the differences in affinity observed for fluvoxamine and fluoxetine in comparison to other SSRIs lacking a trifluoro group in subsite B. The aromatic substituents of the SSRIs are arranged ~90° relative to Try176 and Ile172 in subsite B, but the distances to Tyr176 and Ile172 diverge between inhibitors. In subsite C, the naphthalene group of sertraline is localized 'higher' than the benzofuran and fluorophenyl groups of (S)-citalopram and paroxetine.
A rare autism-associated mutation in DAT (Thr356Met) has recently been shown to stabilize the outward-open conformation in LeuT and to induce hyperactive locomotion in flies 43 . Dopamine uptake of the DAT mutant is markedly decreased as a result of the catalysis of dopamine efflux. The equivalent residue in SERT is Thr371, which is located in TM7, near Na1 and Cl -ion-binding sites. Thr371 probably interacts with Tyr289 in TM5, and substitution of a larger methionine side chain would disrupt this interaction and potentially prevent closure of the extracellular gate.
Together, the SERT-SSRI complexes provide new insights into how pharmacophores of different drugs participate in interactions within the central binding site, all of which stabilize the outwardopen conformation of the transporter. Through structure analysis, how mutations alter the functions of neurotransmitter transporters can be determined more precisely. We anticipate that these studies should provide a blueprint for the development of new therapeutic agents for the treatment of depression and anxiety disorders. 
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